Elevated plasma levels of interleukin-1 receptor antagonist are associated with decreased cellular BCL-2 oncoprotein expression in B-chronic lymphocytic leukemia

Cancer Biother Radiopharm. 1998 Oct;13(5):383-5. doi: 10.1089/cbr.1998.13.383.

Abstract

Plasma IL-1Ra levels and cellular BCL-2 oncoprotein expression were measured in a total of forty blood samples obtained from twenty-eight B-CLL patients and four healthy subjects. High IL-1Ra plasma levels (as defined by mean + three times standard deviation of normal controls) were observed in eleven samples (ten patients) which showed a significantly decreased cellular expression of BCL-2 protein (14.7 +/- 16.3% of cells as determined by immunofluorescence) when compared to B-CLL samples with no elevated IL-1Ra (BCL-2, 31.0 +/- 18.6%; p < or = 0.0115). Albeit correlational only, our results may encourage further experiments to elucidate potential regulatory effects of IL-1Ra for cellular BCL-2 oncoprotein expression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Biomarkers, Tumor / blood
  • Female
  • Humans
  • Interleukin 1 Receptor Antagonist Protein
  • Leukemia, Lymphocytic, Chronic, B-Cell / blood*
  • Leukocytes, Mononuclear / chemistry
  • Leukocytes, Mononuclear / pathology
  • Male
  • Middle Aged
  • Proto-Oncogene Proteins c-bcl-2 / blood*
  • Receptors, Interleukin-1 / antagonists & inhibitors
  • Reference Values
  • Sialoglycoproteins / blood*

Substances

  • Biomarkers, Tumor
  • IL1RN protein, human
  • Interleukin 1 Receptor Antagonist Protein
  • Proto-Oncogene Proteins c-bcl-2
  • Receptors, Interleukin-1
  • Sialoglycoproteins